A New Framework for High-Efficiency Drug Development

A research team under the direction of the Medical University of Vienna has identified a potential new method for drug development in a recently published review.

Image credit: paulista/Shutterstock.com

The emphasis is on targeted modulation of specific intracellular signaling proteins to manage disease-relevant signaling pathways while minimizing adverse effects. The findings, published in the journal Trends in Pharmacological Sciences, broaden the range of methods available for generating personalized therapies, including for the treatment of neurological diseases.

The research is conducted on β-arrestins, which play many roles in signal transduction. These proteins control, amplify, and guide signals within cells, although they have seldom been used as specific drug targets to date. Recent research indicates that alterations in β-arrestin are linked to several diseases, including brain disorders.

Our research shows how tailor-made peptides, i.e. small protein molecules generated by computational design or derived from chemical libraries, bind specifically to target structures such as receptors or arrestins. In contrast to classic active substances, which often influence cellular signals in a non-specific manner, this approach enables differentiated control of signaling pathways.

Christian Gruber, Associate Professor, Center for Physiology and Pharmacology, Medical University of Vienna

Cyclic and nature-inspired peptides, which are ring-shaped molecules based on natural blueprints, are especially intriguing in this context because they are highly stable and target specific cellular signaling systems.

“In this way, our research expands the toolkit for developing precision therapies that are potentially more effective and better tolerated,” Gruber and his team summarized the relevance of their study.

New Perspective on Neurological Diseases

Altering β-arrestins targets neurological diseases like Alzheimer's and tumors like glioblastoma, providing new therapy options. To be successful in these applications, peptides must be tiny, stable, and ring-shaped (cyclic), allowing them to enter cells and, ideally, traverse the blood-brain barrier.

That's why we are already working on methods to deliver peptides specifically to their site of action in the tissue and to exert their effect as precisely as possible.

Christian Gruber, Associate Professor, Center for Physiology and Pharmacology, Medical University of Vienna